Overview

Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The proposed study is a Type 1 hybrid effectiveness-implementation trial. Individuals with opioid use disorder in county jails throughout the state of Maryland will be randomly assigned within gender within jail to one of two groups: Arm 1. XR-B (n=120). XR-B in jail followed by 6 monthly injections post-release at a community treatment program. Arm 2. XR-NTX (n=120). One injection of XR-NTX in jail, followed by 6 monthly injections post-release at a community treatment program.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Friends Research Institute, Inc.
Treatments:
Buprenorphine
Naltrexone